PreciseMent
AI-driven Molecular Testing to Personalize Mental Health Treatment
Company Overview
Snapshot
Founded in January 2021 by Rubek Aknin and Sonia Berreh-Aknin, PreciseMent operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing its AI-driven molecular testing platform.
Business overview
PreciseMent is a Health Tech & Life Sciences company specializing in AI-driven molecular testing to personalize mental health treatment. The company aims to reduce the time it takes to match individuals with psychiatric and mood disorders to the most appropriate treatment. Its core technology leverages biology, multiomics, and artificial intelligence to capture individual patient differences at the genetic and molecular level, creating biosignatures for precision medicine. PreciseMent operates in the Digital Medical Diagnostics sector, serving patients and healthcare providers.
Company Intelligence Q&A
- What is PreciseMent's primary focus?
- PreciseMent focuses on AI-driven molecular testing to personalize mental health treatment, aiming to match individuals with psychiatric and mood disorders to the most appropriate therapies.
- When was PreciseMent founded?
- PreciseMent was founded in January 2021.
- Who are the founders of PreciseMent?
- PreciseMent was co-founded by Rubek Aknin and Sonia Berreh-Aknin.
- What technology does PreciseMent utilize?
- PreciseMent utilizes a unique methodology that combines biology, multiomics technology, and artificial intelligence to identify genetic and molecular biosignatures for precision medicine in mental health.
- What markets does PreciseMent serve?
- PreciseMent operates in the Digital Medical Diagnostics sector, targeting patients and healthcare providers to improve treatment outcomes for psychiatric and mood disorders.